AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Shell Q1 Profit Surges to Two-Year High as Dividend Rises Despite War-Driven Debt Pressure 
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges 
TEL AVIV, Israel, May 01, 2018 -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, May 17 at 8:30am Eastern Time to report first quarter ended March 31, 2018 financial results.
Thursday, May 17th @ 8:30am Eastern Time
US Domestic: 877-222-6394
International: 1-703-925-2702
Conference ID: 9993639
Webcast: https://edge.media-server.com/m6/p/zja7xger
Replays, Available through May 31, 2018
US Domestic: 855-859-2056
International: 1-404-537-3406
Conference ID: 9993639
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
INVESTOR CONTACT:
Michael Rice
LifeSci Advisors, LLC
(646) 597-6979
